1,532
Participants
Start Date
December 5, 2023
Primary Completion Date
November 20, 2025
Study Completion Date
November 20, 2025
Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)
The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)
The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
RECRUITING
Cevaxin - 24 de Diciembre, Panama City
RECRUITING
Cevaxin - Chorrera, Panama City
RECRUITING
Cevaxin-- Avenida Mexico, Panama City
Collaborators (1)
Bill and Melinda Gates Foundation
OTHER
PT Bio Farma
INDUSTRY
Centers for Disease Control and Prevention
FED
Technical Resources International, Inc. (TRI)
UNKNOWN
PATH
OTHER